Lercanidipine Hcl Double-E Pharma (Lercanidipine Hydrochloride)

• Lercanidipine is indicated for conditions within the hypertension disease family and works by lowering elevated blood pressure.
• Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension.
• Secondary hypertension: can be added to other agents when blood pressure remains uncontrolled due to identifiable causes.
• Hypertension in elderly patients: helps achieve target blood pressure in older adults with age‑related vascular stiffness.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle, preventing calcium influx that drives contraction. This results in arterial vasodilation, reduced peripheral resistance, and consequently lower systemic blood pressure without significant negative inotropic effects on the heart.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth, usually on the face or neck.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after standing.
• Tachycardia: increased heart rate.
• Palpitations: awareness of heartbeats.

Serious or Rare Side Effects

• Angioedema: swelling of lips, tongue, or airway requiring urgent care.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Severe allergic reaction: rash, itching, or anaphylaxis.
• Life‑threatening arrhythmias: irregular heart rhythms.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for safety concerns.

• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Heart failure: monitor for worsening symptoms due to fluid retention.
• Pregnancy Category C: discuss potential risks and benefits with the patient.
• Breastfeeding: consider potential exposure to the infant.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma levels.
• Concomitant use with other potent antihypertensives: may cause additive hypotension.
• Grapefruit juice: markedly raises drug concentration.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness.

• Diuretics: monitor electrolytes and blood pressure.
• Beta‑blockers: observe for bradycardia or excessive blood pressure lowering.
• NSAIDs: may blunt antihypertensive response.
• Alcohol: can enhance dizziness and hypotensive effects.